These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Kumar Y; Gurusamy K; Pamecha V; Davidson BR Pancreas; 2007 Aug; 35(2):114-9. PubMed ID: 17632316 [TBL] [Abstract][Full Text] [Related]
3. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648 [TBL] [Abstract][Full Text] [Related]
4. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Schulze G Anticancer Res; 2000; 20(6D):4961-4. PubMed ID: 11326647 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Goonetilleke KS; Mason JM; Siriwardana P; King NK; France MW; Siriwardena AK Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054 [TBL] [Abstract][Full Text] [Related]
7. CA 19-9 in pancreatic cancer. Ritts RE; Pitt HA Surg Oncol Clin N Am; 1998 Jan; 7(1):93-101. PubMed ID: 9443988 [TBL] [Abstract][Full Text] [Related]
8. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer. Novotný I; Dítĕ P; Dastych M; Záková A; Trna J; Novotná H; Nechutová H Hepatogastroenterology; 2008; 55(85):1475-7. PubMed ID: 18795715 [TBL] [Abstract][Full Text] [Related]
9. Tumor markers for pancreatic cancer: what happens when preoperative CA 19-9 is undetectable? Bouvet M Ann Surg Oncol; 2004 Jul; 11(7):637-8. PubMed ID: 15197009 [No Abstract] [Full Text] [Related]
10. Is CA 19-9 a screening marker? Barugola G; Frulloni L; Salvia R; Falconi M Dig Liver Dis; 2009 May; 41(5):325-7. PubMed ID: 19297258 [No Abstract] [Full Text] [Related]
16. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy. Hardt PD; Ewald N Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806 [TBL] [Abstract][Full Text] [Related]
17. [The status of early detection of pancreatic cancer]. Klapdor R Internist (Berl); 1989 Nov; 30(11):752-8. PubMed ID: 2691436 [No Abstract] [Full Text] [Related]
18. [Immunohistologic photometric quantification of pyruvate kinase content of rat tumors]. Bahnemann R; Domingo M; Eigenbrodt E; Reinacher M Verh Dtsch Ges Pathol; 1990; 74():373-5. PubMed ID: 1708618 [TBL] [Abstract][Full Text] [Related]
19. Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells. Zhou W; Capello M; Fredolini C; Racanicchi L; Dugnani E; Piemonti L; Liotta LA; Novelli F; Petricoin EF Anal Bioanal Chem; 2013 May; 405(14):4937-43. PubMed ID: 23508580 [TBL] [Abstract][Full Text] [Related]
20. Use of cyst fluid CEA, CA19-9, and amylase for evaluation of pancreatic lesions. Snozek CL; Mascarenhas RC; O'Kane DJ Clin Biochem; 2009 Oct; 42(15):1585-8. PubMed ID: 19576876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]